FDA guidance
E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or…
FDA guidance · Final · issued Dec 5, 2022
Key facts
| Title | E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials |
|---|---|
| Status | Final |
| Issue date | Dec 5, 2022 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Docket number | FDA-2019-D-1828 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents